Cancers, Vol. 12, Pages 1218: Past, Present and Future of Epigenetics in Adrenocortical Carcinoma

Cancers, Vol. 12, Pages 1218: Past, Present and Future of Epigenetics in Adrenocortical Carcinoma Cancers doi: 10.3390/cancers12051218 Authors: Madeleine Ettaieb Thomas Kerkhofs Manon van Engeland Harm Haak DNA methylation profiling has been suggested a reliable technique to distinguish between benign and malignant adrenocortical tumors, a process which with current diagnostic methods remains challenging and lacks diagnostic accuracy of borderline tumors. Accurate distinction between benign and malignant adrenal tumors is of the essence, since ACC is a rare but aggressive endocrine disease with an annual incidence of about 2.0 cases per million people per year. The estimated five-year overall survival rate for ACC patients is <50%. However, available treatment regimens are limited, in which a radical surgical resection is the only curable option. Nevertheless, up to 85% of patients with radical resection show recurrence of the local disease often with concurrent metastases. Adrenolytic therapy with mitotane, administered alone or in combination with cytotoxic agents, is currently the primary (palliative) treatment for patients with advanced ACC and is increasingly used in adjuvant setting to prevent recurrence. Prognostic stratification is important in order to individualize adjuvant therapies. On April 1, 2020, there were 7404 publications on adrenocortical carcinoma (adrenocortical carcinoma) OR adrenocortical carcinoma [MeSH Terms]) OR adrenal cort...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research